⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of hVIVO plc and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
hVIVO plc
↗London, United Kingdom
hVIVO is a leading full-service early-phase Contract Research Organisation (CRO) and the global leader in human challenge clinical trials. The company specializes in testing infectious and respiratory disease vaccines and therapeutics, providing end-to-end clinical development services from preclinical stages through Phase II trials.
Following the strategic acquisition of CRS (Clinical Research Services) in early 2025, hVIVO has consolidated its operations, including Venn Life Sciences and Cryostore, under a single brand. The company operates state-of-the-art quarantine facilities in London and clinical sites in Germany (Mannheim and Kiel), offering integrated expertise in virology, immunology, and clinical trial management.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:CRO
Sub-Industry:Early-phase clinical trials / Infectious disease
SIZE & FINANCIALS
Employees:501-1000
Revenue:$100M-$200M
Founded:1989
Ownership:public
Status:operating
FUNDING
Investors:IP Group, Aquarius Equity Partners
STOCK
Exchange:LSE
Ticker:HVO
Market Cap:£0.04B
PIPELINE
Stage:Phase 2
Lead Drug Stage:N/A (CRO Service Provider)
Modalities:Vaccines, Antivirals
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:CRS (Clinical Research Services), Venn Life Sciences, Cryostore
Key Partnerships:Global biopharma and emerging biotech companies (serves 7 of the top 10 global biopharma companies)
COMPETITION
Position:Leader
Competitors:ICON, IQVIA, Parexel, Syneos Health
LEADERSHIP
Key Executives:
Andrew Catchpole - Chief Scientific Officer
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with hVIVO plc. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.